Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hye Suk Hwang

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Vaccines|September 23, 2018
Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza VirusKi-Hye Kim, Young-Man Kwon, Young-Tae Lee, et al.
Journal for Immunotherapy of Cancer|March 21, 2025
Thermoresistant flagellin-adjuvanted cancer vaccine combined with photothermal therapy synergizes with anti-PD-1 treatmentJayalakshmi Thiruppathi, Veena Vijayan, Hye Suk Hwang, et al.
Journal of Virology|September 11, 2015
Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T CellsKi-Hye Kim, Young-Tae Lee, Hye Suk Hwang, et al.
Vaccine|June 22, 2014
AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protectionYu-Na Lee, Min-Chul Kim, Young-Tae Lee, et al.
Virology|September 11, 2018
Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccineKi-Hye Kim, Young-Man Kwon, Young-Tae Lee, et al.
Virology|January 2, 2015
Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory diseaseYu-Na Lee, Hye Suk Hwang, Min-Chul Kim, et al.
Antiviral Research|June 1, 2019
The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvantsYouri Lee, Eun-Ju Ko, Ki-Hye Kim, et al.
Expert Review of Vaccines|August 4, 2022
Vaccines against SARS-CoV-2 variants and future pandemicsTaeyoung Park, Hyogyeong Hwang, Suhyeong Moon, et al.
Plos One|October 16, 2015
Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune CellsKi-Hye Kim, Young-Tae Lee, Hye Suk Hwang, et al.
Journal of Virology|March 27, 2026
Type I interferon signaling is required for resistance to primary influenza virus infection and vaccine-induced long-term immunityKi-Hye Kim, Hye Suk Hwang, Surya Sekhar Pal, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Vaccines|September 23, 2018
Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza VirusKi-Hye Kim, Young-Man Kwon, Young-Tae Lee, et al.
Journal for Immunotherapy of Cancer|March 21, 2025
Thermoresistant flagellin-adjuvanted cancer vaccine combined with photothermal therapy synergizes with anti-PD-1 treatmentJayalakshmi Thiruppathi, Veena Vijayan, Hye Suk Hwang, et al.
Journal of Virology|September 11, 2015
Virus-Like Particle Vaccine Containing the F Protein of Respiratory Syncytial Virus Confers Protection without Pulmonary Disease by Modulating Specific Subsets of Dendritic Cells and Effector T CellsKi-Hye Kim, Young-Tae Lee, Hye Suk Hwang, et al.
Vaccine|June 22, 2014
AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protectionYu-Na Lee, Min-Chul Kim, Young-Tae Lee, et al.
Virology|September 11, 2018
Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccineKi-Hye Kim, Young-Man Kwon, Young-Tae Lee, et al.
Virology|January 2, 2015
Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory diseaseYu-Na Lee, Hye Suk Hwang, Min-Chul Kim, et al.
Antiviral Research|June 1, 2019
The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvantsYouri Lee, Eun-Ju Ko, Ki-Hye Kim, et al.
Expert Review of Vaccines|August 4, 2022
Vaccines against SARS-CoV-2 variants and future pandemicsTaeyoung Park, Hyogyeong Hwang, Suhyeong Moon, et al.
Plos One|October 16, 2015
Alum Adjuvant Enhances Protection against Respiratory Syncytial Virus but Exacerbates Pulmonary Inflammation by Modulating Multiple Innate and Adaptive Immune CellsKi-Hye Kim, Young-Tae Lee, Hye Suk Hwang, et al.
Journal of Virology|March 27, 2026
Type I interferon signaling is required for resistance to primary influenza virus infection and vaccine-induced long-term immunityKi-Hye Kim, Hye Suk Hwang, Surya Sekhar Pal, et al.
Pageof 6